A B S T R A C T Cetiedil is a potential antisickling agent whose major effect appears to be at the erythrocyte membrane. To test the hypothesis that cetiedil alters cation transport, we studied the effect of the drug in promoting changes in cell water (We), cell sodium (Naj), and cell potassium (Kc). Results are quite different depending on the presence or near absence of intracellular ATP. With fresh cells, 100 MM cetiedil causes little change in net cation or water movements compared with control cells incubated for 2 h. At cetiedil concentrations >100 AM, however, net movements of sodium and potassium increase considerably, and cell swelling results from a net Nac gain that exceeds a net Kc loss. All water movements can be accounted for by cetiedil-induced net cation movements. When 100 MM ouabain is added along with cetiedil, net Nac gain, net Kc loss, and net Wc gain are all increased compared with results obtained with cetiedil alone. External calcium inhibits cetiedil-induced changes in cation transport. With cells depleted of their ATP, cetiedil inhibits the typical potassium loss that occurs in the presence of external calcium; net sodium uptake changes little under these conditions, regardless of the presence or absence of external calcium. Our findings indicate a complex mode of action for cetiedil on the erythrocyte membrane, and support the hypothesis that the antisickling effect of the drug observed in vitro results from dilution of intracellular hemoglobin secondary to net salt and water gain. INTRODUCTION Cetiedil, a-cyclohexyl-3-thiophenacetic acid 2-(hexahydro-lH-azepin-1-yl) ester, has aroused considerable interest recently as a potentially useful agent in the treatment of patients with sickle cell disease. The antisickling effect of cetiedil was first reported by Cabannes (1), who conducted a clinical study on the Ivory Coast that suggested that the drug has a beneficial effect on patients with acute vaso-occlusive crises. Currently, cetiedil is used in Europe for treatment of ischemic leg pain due to vascular disease. Known pharmacological properties of the drug include vascular smooth muscle relaxation, inhibition of phosphodiesterase, blockade of the effects of bradykinin and serotonin, analgesia, and inhibition of platelet aggregation (2) . While many of these properties may benefit the patient with severe sickle cell crisis, the mechanism by which the drug acts on the erythrocyte to prevent sickling has not yet been elucidated.
The antisickling effect of cetiedil in vitro is evident at drug concentrations from 50 to 500 MM (3, 4) . At the lowest effective concentration, this represents a drug-to-hemoglobin tetramer ratio of 1:100. The findings that cetiedil prevents sickling with only slight change in the minimal gelling concentration of deoxy hemoglobin S and with no change in the oxygen affinity of sickle cells (3, 4) seemed to rule out an inhibitory effect on the hemoglobin molecules as the main mode of action. A key observation by Asakura and co-workers (3) was that the hematocrit of sickle cells incubated overnight with 400 MM cetiedil increased by as much as 20%. They proposed that the primary site for drug action is at the cell membrane leading to cell swelling and a secondary dilution of hemoglobin. This hypothesis is attractive in explaining the drug's antisickling property since it is well known that small increases in cell water content can greatly delay cell sickling, the delay time for gelatin being inversely proportional to the 30th power of the hemoglobin concentration (5 ) and used without further purification. Unless specified otherwise, incubation solutions contained: 5 mM KCI, 10 mM glucose, 10 mM Na-TES or Mg-TES [Ntris(hydroxymethyl)methyl-2-aminoethane sulfonic acid] adjusted to pH 7.4 at 37°C, and sufficient NaCl (-160 mM) to adjust osmolality to 300 mosmol. TES buffers were prepared as described previously (6) .
To deplete intracellular ATP, cells were incubated for 1 Abbreviations used in this paper: K,, cell potassium; Na,, Table I .
RESULTS
To investigate the effect of cetiedil on erythrocyte membrane permeability to cations, we incubated fresh cells for 1 h in the absence and presence of cetiedil at concentrations ranging from 100 to 500 ,uM. The experiments were performed twice with cells from patients with homozygous sickle cell disease and twice with control cells. Values for Nac and Kc are plotted in Fig. 1 . Increasing concentrations of cetiedil cause the cells to become increasingly permeable to both sodium and potassium so that Nac increases and Kc decreases. There was no measurable difference in the net cation movements observed when the effect of cetiedil on sickle erythrocytes was compared to the effect of the drug on normal erythrocytes. At 500 uM cetiedil, hemolysis was prominent with both cell types, approaching 50% in some experiments following 1 h of incubation.
The time-course of cetiedil's effect on net cation movements in normal erythrocytes is shown in Fig. 2 .
In the presence of 300 ,iM cetiedil, net sodium gain exceeds net potassium loss over the interval measured, and the cells swell. Cell swelling is so rapid with this concentration of cetiedil that a small, but measurable increase in cell water was observed even for the zero time samples. at a rapid rate (Fig. 5) . This immediate potassium efflux is slowed dramatically by increasing concentrations of cetiedil, confirming an earlier report (9) that cetiedil inhibits the so-called "Gardos effect" (10) . Under these conditions of nearly absent intracellular ATP, ouabain was without effect (data not shown). Two additional points are apparent from consideration of Fig. 5 . First, although increasing concentrations of cetiedil promote net Nar gain, the effect is trivial compared to the striking net Nac gain observed when cetiedil is added to fresh erythrocytes (compare Fig. 2) . Second, maximal inhibition of net Kc loss in ATP-depleted cells occurs by 100 ,uM cetiedil, a drug concentration that has minimal effect on fresh erythrocytes after 1 h incubation (compare Fig. 1 ).
One major difference in the experimental design for fresh and ATP-depleted erythrocytes is that incubations with energy-depleted cells contained calcium to facilitate the Gardos effect (10) while those with fresh cells contained no calcium. To explore a possible role for external calcium in preventing permeability increases to sodium caused by cetiedil, experiments with ATP-depleted erythrocytes were repeated in the presence and absence of calcium. Results of a representative experiment are illustrated by Fig. 6 . In the absence of external calcium, cells exposed to cetiedil (open squares) lose little potassium, and net sodium gain is only slightly increased over that observed with calcium present. Although such stimulation of net sodium gain is reproducible upon removing calcium from the incubation, it is much smaller than that observed when fresh erythrocytes are treated with cetiedil (open triangles). -.
-.
The inhibitory effect of calcium on cetiedil-induced changes in net sodium influx is much more apparent in fresh erythrocytes (Fig. 7) . Cells were incubated 1 h with 300 ,uM cetiedil and different concentrations of calcium. As external calcium is increased, cetiedilinduced net Na, gain and K. loss are both inhibited.
With 5 mM external calcium, there is little net change in cell cation content, and cell volume is stable.
DISCUSSION
Since formulation of the equations of Hofrichter and co-workers (5), it has become evident that one way to slow the rate of sickling is to dilute the intracellular hemoglobin. Under normal circumstances, the erythrocyte maintains a constant volume, and thus constant hemoglobin concentration, by balancing the passive movements of sodium into and potassium out of the cell with the active extrusion of sodium and active uptake of potassium via the ATP-dependent, Na-K coupled pump (11) . Water and small anions are, for practical considerations, at equilibrium. In theory, intracellular hemoglobin concentration can be altered by three different general mechanisms involving the cell membrane. These are: (a) changes in plasma osmolality, (b) changes in membrane permeability to cations, and (c) changes in the efficiency of the pump in maintaining the erythrocyte at a steady state.
Several clinical trials of sickle cell disease have been carried out that were designed to lower intracellular hemoglobin concentration by lowering plasma osmolality. In one such trial, intravenous administration of distilled water to two patients with sickle cell trait and gross hematuria successfully stopped the hematuria, presumably by reversing sickling in the hypertonic renal medulla (12) . In another trial, vigorous intra- venous hydration with hypotonic fluids was claimed to shorten the recovery phase from acute vaso-occlusive crises (13) . More recently, the chronic administration of 1-desamino-8-D-arginine vasopressin, which lowers plasma sodium and thus osmolality, was shown to decrease mean hemoglobin concentration and to protect susceptible patients from vaso-occlusive crises (14) . The manipulation of the Na-K pump or of cell membrane cation permeability specifically to prevent sickling represents an area that to date remains largely unexplored. Cetiedil is the first drug to be reported that inhibits erythrocyte sickling by acting directly on the cell membrane, causing cell swelling (3). The results of this investigation show that cetiedil increases cell volume in fresh erythrocytes by promoting net salt gain. Although cetiedil causes increased fluxes of both sodium and potassium, net Nac gain exceeds net Kc loss, and rapid cell swelling results (Fig. 2) . Such excess of Na, gain over Kc loss occurs over the entire range of cetiedil concentrations tested (Fig. 1) . In all cases, sufficient salt is accumulated to account for net water gain (Fig. 3) , and there is no need to invoke alternative mechanisms for cell volume increases. The concentration of cetiedil required to produce measurable changes in membrane permeability (>100 AM, Fig. 1 (3, 4) . Approximately 2 mg cetiedil/kg body wt would be required to achieve intravascular concentrations of 100 ,uM in vivo. If administered as a single intravenous dose, this would require 10 times more drug than is given typically to human subjects (1). However, little is known about the metabolism and excretion of cetiedil, and blood levels have not been reported. Single intravenous injections of 2 mg cetiedil/kg body wt have been administered successfully to animals (2) .
Studies performed to help clarify the mechanism of cetiedil's action on normal erythrocytes are thus far inconclusive. Both sodium uptake and potassium loss are further enhanced when ouabain is added to fresh' cell suspensions containing cetiedil (Fig. 4) . This finding is consistent with a hypothesis that cetiedil acts at some membrane locus separate from that occupied by the Na-K pump. Thus, with ouabain absent and the pump functioning, the cell extrudes some of the sodium gained and takes up some of the potassium lost in the presence of (Fig. 6 ). Whether this lack of effect is due to a nonfunctioning pump, substrate depletion, or inhibitor accumulation remains to be determined. Normal erythrocytes depleted of their ATP undergo a well-described loss of KC1 and water that depends on extracellular calcium (10) . The efficacy of cetiedil in blocking net KC1 loss that we observe under such conditions (Fig. 5) confirms an earlier report of the inhibitory nature of the drug (9) . The physiological significance of such inhibition in the absence of ATP remains to be determined. In our experiments, it was necessary to deplete the cells of >90% of their ATP before inhibition, rather than stimulation, of net fluxes by cetiedil was achieved. Inhibition of the calciuminduced potassium fluxes by cetiedil in ATP-depleted cells (Figs. 5, 6 ), and reciprocal inhibition of cetiedilinduced net cation fluxes by calcium in ATP-replete cells (Fig. 7) , may suggest a common membrane site for the action of calcium and cetiedil. Experiments are now underway to determine whether extracellular or intracellular calcium is the important variable.
Clearly, the mechanism of action for cetiedil's effect on cation transport remains unknown. Before any definitive statements can be made about the site of action of the drug, unidirectional flux studies must be carried out with and without ouabain and with and without intracellular ATP. In addition, interpretations of mechanism of action obtained with normal erythrocytes will need to be extended to sickle cells. The effect of the drug on leukocytes and platelets remains to be elucidated. We believe that further studies with cetiedil and related compounds will not only prove useful in the search for anti-sickling agents, but will also help clarify the basic physiology of the erythrocyte membrane transport system.
